CD8A and neoplasm: Vaccination generated modest circulating OVA-specific CD8+ T cell responses (Fig. 1a), with preferential trafficking of tumor-specific CD8+ T cells into the TME (Fig. 1b) but did not improve tumor progression over untreated animals (Fig. 1c).